Stockholders' Equity (Details Narrative) - USD ($) |
9 Months Ended | |||||
|---|---|---|---|---|---|---|
Sep. 30, 2019 |
Sep. 30, 2019 |
Sep. 30, 2018 |
Sep. 29, 2019 |
Aug. 31, 2019 |
Dec. 31, 2018 |
|
| Sale of preferred stock, number of preferred shares sold | ||||||
| Preferred stock, shares issued | ||||||
| Preferred stock, shares outstanding | ||||||
| Repayment made directly by investor for clinical trial expenses | $ 210,832 | |||||
| Amount paid included in prepaid expense and other current assets | $ 180,119 | $ 180,119 | ||||
| Preferred stock, shares authorized | 1,000,000 | 1,000,000 | 10,000,000 | 10,000,000 | ||
| Common stock, shares authorized | 100,000,000 | 100,000,000 | 350,000,000 | 350,000,000 | ||
| PoC Capital [Member] | Pledge Agreement [Member] | ||||||
| Maximum revolving line of credit | $ 900,000 | $ 900,000 | $ 1,800,000 | |||
| PoC Capital [Member] | Pledge Agreement [Member] | Until Certain Milestones Payment [Member] | ||||||
| Common stock, forfeited | 396,476 | |||||
| Warrants, forfeited | 396,476 | |||||
| PoC Capital [Member] | CRO [Member] | ||||||
| Payment for subscription receivable | $ 689,168 | |||||
| X | ||||||||||
- Definition Payment for subscription receivable. No definition available.
|
| X | ||||||||||
- Definition Repayment made directly by investor for clinical trial expenses. No definition available.
|
| X | ||||||||||
- Definition The maximum number of common shares permitted to be issued by an entity's charter and bylaws. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. No definition available.
|
| X | ||||||||||
- Definition Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|